HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rituximab as a first-line treatment in pediatric neuromyelitis optica spectrum disorder.

AuthorsGiorgia Olivieri, Viviana Nociti, Raffaele Iorio, Maria Chiara Stefanini, Francesco Antonio Losavio, Massimiliano Mirabella, Paolo Mariotti
JournalNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (Neurol Sci) Vol. 36 Issue 12 Pg. 2301-2 (Dec 2015) ISSN: 1590-3478 [Electronic] Italy
PMID26292790 (Publication Type: Case Reports, Letter)
Chemical References
  • Aquaporin 4
  • Autoantibodies
  • Rituximab
Topics
  • Aquaporin 4 (immunology)
  • Autoantibodies (immunology)
  • Child
  • Female
  • Humans
  • Neuromyelitis Optica (diagnosis, drug therapy)
  • Rituximab (administration & dosage, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: